Loading... Please wait...

Our Newsletter


ABT-888 (Veliparib) | PARP1/2 inhibitor

  • ABT-888 (Veliparib).jpg
  • ABT-888 (Veliparib), 400x400px, png
Price:
$119.00
Catalog #:
C2888-5
Quantity:


Product Description

ABT-888 (Veliparib) is an orally-available, benzimidazole-based inhibitor of poly(ADP-ribose) polymerase with Ki values of 5.2 and 2.9 nM, for PARP1 and PARP2, respectively. [1] ABT-888 exhibits activity in C41 whole cells at an EC50 of 2 nM [2], and inhibits PAR formation in cells at an EC50 of 4.5 nM. [3]

ABT-888 efficiently crosses the blood-brain barrier and has been shown to potentiate DNA-damaging agents such as temozolomide, cisplatin, carboplatin, cyclophosphamide, irinotecan, and radiation. [1, 4] Treatment with temozolomide in the S phase generated higher levels of double-stranded DNA breaks and general higher levels of cytoxicity.


Technical information:

Chemical Formula:   C13H16N4O
CAS #:   912444-00-9,912445-05-7
Molecular Weight:   244.29
Purity:   > 98%
Appearance:   White solid
Chemical Name:   (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide
Solubility:   Up to 75 mM in DMSO
Synonyms:   ABT-888, ABT 888, ABT888, Veliparib

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. Palma et al., The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res. 2008, 28, 2625-2636. Pubmed ID: 19035287
2. Penning et al., Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J. Med. Chem. 2009, 52, 514-523. Pubmed ID: 19143569
3. Liu et al., Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol. Cancer Res. 2008, 6, 1621-1629. Pubmed ID: 18922977
4. Donawho et al., ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 2007, 13(9), 2728-2737. Pubmed ID: 19143569

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the ABT-888 (Veliparib) | PARP1/2 inhibitor to your wish list.

You Recently Viewed...